# A Study to Assess the Safety of ARGX-213 in Healthy Volunteers

> **NCT06968338** · PHASE1 · COMPLETED · sponsor: **argenx** · enrollment: 88 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** ARGX-213
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06968338
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-11
- **Primary completion:** 2026-03-20
- **Final completion:** 2026-03-20
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06968338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06968338, "A Study to Assess the Safety of ARGX-213 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06968338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*